



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection
as Risk Factor of Long-term Post-COVID Symptoms: The
LONG-COVID-EXP-CM Multicenter Study

César Fernández-de-las-Peñas PhD ,
Oscar J. Pellicer-Valero MSc , Esperanza Navarro-Pardo PhD ,
Domingo Palacios-Ceña PhD , Lidiane L. Florencio PhD ,
Carlos Guijarro PhD , José D. Martín-Guerrero PhD

PII: S1201-9712(22)00007-8
DOI: <https://doi.org/10.1016/j.ijid.2022.01.007>
Reference: IJID 5929

To appear in: *International Journal of Infectious Diseases*

Received date: 4 July 2021
Revised date: 2 January 2022
Accepted date: 4 January 2022

Please cite this article as: César Fernández-de-las-Peñas PhD , Oscar J. Pellicer-Valero MSc , Esperanza Navarro-Pardo PhD , Domingo Palacios-Ceña PhD , Lidiane L. Florencio PhD , Carlos Guijarro PhD , José D. Martín-Guerrero PhD , Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study, *International Journal of Infectious Diseases* (2022), doi: <https://doi.org/10.1016/j.ijid.2022.01.007>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Highlights

- This multicentre study included 1,969 COVID-19 hospitalized patients.
- A higher number of onset symptoms was associated with more post-COVID symptoms
- Dyspnea and headache symptoms at onset are associated with post-COVID symptoms.

Journal Pre-proof

Short Communication

Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study

César Fernández-de-las-Peñas¹ PhD; Oscar J. Pellicer-Valero² MSc; Esperanza Navarro-Pardo³ PhD; Domingo Palacios-Ceña¹ PhD; Lidiane L. Florencio¹ PhD; Carlos Guijarro^{4,5} PhD; José D. Martín-Guerrero² PhD

Affiliations

¹ Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid. Spain.

² Intelligent Data Analysis Laboratory, Department of Electronic Engineering, ETSE (Engineering School), Universitat de València (UV), Valencia, Spain.

³ Department of Developmental and Educational Psychology, Universitat de València (UV), València, Spain

⁴ Department of Medicine, Universidad Rey Juan Carlos (URJC), Madrid. Spain.

⁵ Department of Internal Medicine, Hospital Universitario Fundación Alcorcón, Madrid, Spain

Corresponding / reprint requests author:

César Fernández-de-las-Peñas
Facultad de Ciencias de la Salud
Universidad Rey Juan Carlos
Avenida de Atenas s/n
28922 Alcorcón, Madrid, SPAIN
Email: cesar.fernandez@urjc.es

Telephone number: + 34 91 488 88 84

Fax number: +34 91 488 89 57

Abstract

Objective: This multicenter study investigated clinical risk factors associated with the number of long-term post-COVID symptoms.

Methods: Clinical features, symptoms at hospital admission, hospitalization data, and the number of post-COVID symptoms was systematically assessed from patients recovered from COVID-19 at four hospitals in Madrid (Spain) from February 20 to May 31, 2020.

Results: Overall, 1,969 patients (46.5% women, age: 61, SD: 16 years) were randomly assessed at 8.4 months (SD 1.5) after hospital discharge. Female gender (OR1.82, 95%CI 1.57-2.10), number of morbidities (OR1.182, 95%CI 1.08-1.29), number of symptoms at hospital admission (OR1.309, 95%CI 1.15-1.49) and days at the hospital (OR1.01, 95%CI 1.007-1.017) were associated (all, $P<0.001$) with more long-term post-COVID symptoms. Further, vomiting (OR1.78, 95%CI 1.26-2.52), throat pain (OR1.36, 95%CI 1.02-1.81), diarrhoea (OR1.51, 95%CI 1.25-1.82), dyspnea (OR1.20, 95%CI 1.01-1.41), or headache (OR1.50, 95%CI 1.28-1.75) as symptoms at hospital admission were also associated (all, $P<0.01$) with a higher number of post-COVID symptoms.

Conclusion: This multicenter study found that a higher number of symptoms at hospital admission was the most relevant risk factor for developing more post-COVID symptoms, supporting the assumption that a higher symptom load at the acute phase is associated with a greater likelihood of long-term post-COVID symptoms.

Key words: COVID-19, persistent, symptoms, risk factors, acute phase.

Introduction

The presence of post-COVID symptoms ranges from 35% to 60% (Fernández-de-las-Peñas et al., 2021). Identification of risk factors is needed for an early monitoring of individuals at a high risk of developing post-COVID symptoms, yet current data is still limited (Iqbal et al., 2021). Potential identified risk factors described in former literature include female sex, more onset-symptoms (higher symptom load), older age, longer hospital stance, and higher number of comorbidities (Yong et al., 2021). Nevertheless, contradictory results are also observed between studies. Further, most of studies included samples of <300 patients and recruited from single centers (Iqbal et al., 2021). A study including a large number of COVID-19 patients reported a prevalence of long-term sick leave from work of 5.8% (Jacobs et al., 2021). These authors found that female, older age and co-morbid medical conditions were significantly associated with long-term sick leave (Jacobs et al., 2021). We describe here a large multicenter study investigating clinical risk factors related with hospitalized associated with the number of long-term post-COVID symptoms in a large population sample.

Methods

The LONG-COVID-EXP-CM is a multicenter cohort study including individuals hospitalized with a diagnosis of SARS-CoV-2 during the first wave of the pandemic in five public hospitals in Madrid (Spain). A sample of 400 individuals from each hospital was randomly selected. All Local Ethics Committees approved the study (HCSC20/495E, HSO25112020, HUFA 20/126, HUIL/092-20, HUF/EC1517). Informed consent was obtained from all participants. Participants were scheduled for a telephone interview conducted by experienced healthcare professionals, were systematically asked about a list of post-COVID symptoms (multiple symptoms could be selected by the

same patient), but were free to report any additional symptom that they experienced at the time of study. Clinical data (i.e., gender, age, height, weight, comorbidities), COVID-19 symptoms at hospital admission and hospitalization (i.e., days at hospital, intensive care unit admission) data were collected from medical records.

Mean and standard deviation (SD) or percentages were calculated. Missing values were imputed using median imputation. Multivariate logistic regressions were conducted to analyze associations between clinical and hospitalization variables with the number of post-COVID symptoms (dependent variable) using Python's library statsmodels 0.11.1. Adjusted odds ratio (OR) and confidence intervals (95%CI) were calculated.

Results

From 2,000 patients randomly selected and invited to participate, a total of 1,969 (46.5% women, age: 61, SD: 16 years) participated. The most prevalent symptoms at hospital admission were fever (74.6%), dyspnea (31.5%), and myalgia (30.7%). Almost 57.5% of the individuals (n=1,133) reported at least one comorbidity. Participants were assessed 8.4 months (SD 1.5) after hospital discharge. Almost one out of five patients (n=367, 18.7%) were free of post-COVID symptoms, whereas 34.4% (n=679) experienced ≥ 3 post-COVID symptoms. The mean number of post-COVID symptoms was 1.9 (SD 1.4). The most frequent long-term post-COVID symptoms included fatigue (61.3%) and dyspnea (23.3%).

Female gender (OR1.82, 95%CI 1.57-2.10), number of COVID-19 symptoms at hospital admission (OR1.309, 95%CI 1.15-1.49), number of pre-existing medical comorbidities (OR1.182, 95%CI 1.08-1.29), and days at hospital (OR1.01, 95%CI 1.007-1.017) were independently associated (all, $P < 0.001$) with more long-term post-COVID

symptoms: the higher the number of COVID-19 onset symptoms or the higher the number of co-morbidities, the higher the number of post-COVID symptoms (**Figure**). No specific co-morbidity (e.g., obesity, hypertension) was associated with a greater number of post-COVID symptoms. Some specific symptoms at the acute phase were also independently associated (all, $P < 0.01$) with a higher number of long-term post-COVID symptoms (**Table**): vomiting (OR1.78, 95%CI 1.26-2.52), throat pain (OR1.36, 95%CI 1.02-1.81), diarrhoea (OR1.51, 95%CI 1.25-1.82), dyspnea (OR1.20, 95%CI 1.01-1.41), or headache (OR1.50, 95%CI 1.28-1.75).

Discussion

This multicenter study found that female gender, a greater number of symptoms at hospital admission, a greater number of pre-existing medical co-morbidities, and a longer stay at the hospital were risk factors for developing more long-term post-COVID symptoms. Among all these risk factors, it seems that a higher number of symptoms at hospital admission was the most relevant for developing more post-COVID symptoms. In fact, the presence of some specific symptoms at hospital admission such as vomiting, throat pain, diarrhoea, dyspnea or headache was also associated to long-term post-COVID symptoms. No specific medical co-morbidity was associated with a greater number of long-term post-COVID symptoms. Our data support previous assumptions that a higher symptom load at the acute phase is associated with a greater likelihood of long-term post-COVID symptoms (Iqbal et al., 2021). The role of previous medical co-morbidities as a risk factor for post-COVID symptom needs further studies. We also observed that female gender was a potential risk factor for post-COVID symptoms, in agreement with previous assumptions (Iqbal et al., 2021). Specific studies investigating sex differences are needed.

Our results should be considered according to some potential weaknesses. First of all, only hospitalized patients participated. Second, we did not collect objective data of COVID-19 disease. Third, the cross-sectional design did not permit to determine cause-and-effect associations.

References

- Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, Navarro-Santana M. Prevalence of Post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. *Eur J Int Med* 2021; 92:55-70.
- Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. *EClinicalMedicine*. 2021; 36: 100899.
- Jacobs L, Koyanagi AI, Smith L, Tanislav C, Konrad M, van der Beck S, Kostev K. Prevalence of and factors associated with long-term COVID-19 sick leave in working-age patients followed in general practices in Germany. *Int J Infectious Diseases* 2021, doi: <https://doi.org/10.1016/j.ijid.2021.06.063>
- Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis* 2021, doi: 10.1080/23744235.2021.192439

Author Contributions

Dr Fernández-de-las-Peñas and Dr. Palacios-Ceña had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Dr. Pellicer-Valero. Supervision: Dr. Martín-Guerrero

Declaration of interests

No conflict of interest is declared by any of the authors

Acknowledgments

We want to acknowledge all participants with COVID-19 of this study for their attention

Role of the Funding Source

The LONG-COVID-EXP-CM is supported by Fondo Europeo De Desarrollo Regional - Recursos REACT-UE del Programa Operativo de Madrid 2014-2020, en la línea de actuación de proyectos de I+D+i en materia de respuesta a COVID 19. The sponsor had no role in the design, collection, management, analysis, or interpretation of the data, draft, review, or approval of the manuscript or its content. The authors were responsible for the decision to submit the manuscript for publication, and the sponsor did not participate in this decision.




Figure: Positive associations between the number of long-term post-COVID symptoms with the number of pre-existing comorbidities (left) or the number of COVID-19 onset-symptoms at hospital admission

Table: Clinical/Hospitalization Data and Post-COVID Symptoms (n=1,969)

Age, mean (SD), years	61 (16)
Gender, male/female (%)	1,054 (53.5%) / 915 (46.5%)
Weight, mean (SD), kg.	75 (15)
Height, mean (SD), cm.	165 (16.5)
Main Symptoms at hospital admission, n (%)	
Fever	1,469 (74.6%)
Dyspnoea	620 (31.5%)
Myalgia	604 (30.7%)
Cough	549 (27.9%)
Headache	332 (16.9%)
Diarrhoea	210 (10.7%)
Anosmia	167 (8.5%)
Throat Pain	102 (5.2%)
Ageusia	66 (3.3%)
Vomiting	55 (2.8%)
Number of medical co-morbidities, n (%)	
None	836 (42.5%)
One	715 (36.3%)
Two	281 (14.2%)
3 or more	137 (7%)
Medical co-morbidities	
Hypertension	514 (26.1%)
Diabetes	236 (12.0%)
Cardiovascular Disease	234 (11.9%)
Asma	126 (6.4%)
Obesity	88 (4.5%)
Chronic Obstructive Pulmonary Disease	77 (3.9%)
Stroke	38 (2.0%)
Rheumatological Disease	31 (1.6%)
Other (Cancer, Kidney Disease)	332 (16.9%)
Stay at the hospital, mean (SD), days	11.3 (11.4)
Intensive Care Unit (ICU) admission	
Yes/No, n (%)	130 (6.6%) / 1,839 (93.4%)
Number of long-term post-COVID symptoms, n (%)	
None	367 (18.7%)
One	436 (22.1%)
Two	488 (24.8%)
3 or more	679 (34.4%)
Long-Term post-COVID symptoms, n (%)	
Fatigue	1,206 (61.3%)
Dyspnoea	459 (23.3%)
Loss memory	341 (17.3%)
Skin Rashes	236 (12.0%)
Brain fog	189 (9.5%)
Attention Disorders	140 (7.1%)
Palpitations	140 (7.1%)
Gastrointestinal Disorders	133 (6.7%)
Ocular/Vision Disorders	116 (5.9%)
Anosmia	80 (4%)
Ageusia	53 (2.7%)
Throat Pain	50 (2.55%)
Diarrhoea	49 (2.5%)
Voice Problems	39 (2%)
COVID-19 Onset Symptom at Hospital Admission	Number Long-term Post-COVID Symptoms
*Dyspnoea (n=620)	2.1 (SD 1.3)
No Dyspnoea (n=1,349)	1.8 (SD 1.4)
*Headache (n=332)	2.2 (SD 1.4)
No Headache (n=1,637)	1.8 (SD 1.3)
*Diarrhoea (n=210)	2.25 (SD 1.4)
No Diarrhoea (n=1,759)	1.8 (SD 1.4)
*Throat Pain (n=102)	2.35 (SD 1.4)
No Throat Pain (n=1,867)	1.85 (SD 1.4)
*Vomiting (n=55)	2.5 (SD 1.4)
No Vomiting (n=1,914)	1.85 (SD 1.3)

* Significant association in the multivariate analysis

Journal Pre-proof